高危前列腺癌根治性前列腺切除术前新辅助内分泌治疗对生存的影响
这项回顾性多中心研究纳入1573例高危前列腺癌患者,比较根治性前列腺切除(RP)与新辅助内分泌治疗联合RP(NHT+RP)的前列腺癌相关死亡(PCRD)。倾向评分校正后,NHT降低PCRD风险(HR 0.5;95%CI 0.32-0.80;P=0.0014),且与放疗存在交互效应(HR 0.3;95%CI 0.21-0.43;P<0.0008)。
要点
- 高危前列腺癌中,NHT+RP较单纯RP降低前列腺癌相关死亡风险(HR 0.5;95%CI 0.32-0.80;P=0.0014)。
- NHT与放疗存在交互效应(HR 0.3;95%CI 0.21-0.43;P<0.0008)。
- 接受辅助放疗者中,NHT+RP组5年PCRD率2.3%,RP组7.5%。
核心结论
- 在高危前列腺癌人群中,倾向评分校正分析显示术前NHT显著降低前列腺癌相关死亡,该效应似乎主要由术后早期加用放疗驱动。
- 作者认为NHT+RP与辅助放疗的具体顺序值得在高危前列腺癌人群中进一步研究。
研究设计与样本
- 回顾性多中心研究,纳入高危前列腺癌患者,高危定义为临床分期T3-4、PSA>20 ng ml-1或穿刺Gleason评分8-10。
- 应用纳入/排除标准后共1573例患者进入分析,其中1170例接受RP,403例接受NHT+RP。
- 采用竞争风险分析比较PCRD,并通过倾向评分校正组间差异。
主要发现
- 中位随访56个月(四分位距29-88)。
- 86例患者死于前列腺癌,106例死于其他原因。
- NHT降低PCRD风险(HR 0.5;95%CI 0.32-0.80;P=0.0014)。
- 观察到NHT与放疗的交互效应(HR 0.3;95%CI 0.21-0.43;P<0.0008)。
- 在接受辅助放疗的患者中,NHT+RP组5年PCRD率为2.3%,RP组为7.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 回顾性设计是可能的局限性。
- 缺乏关于NHT的具体信息是可能的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there is a lack of knowledge regarding a possible effect of NHT on PCRD in the high-risk PCa population. We aimed to analyze the effect of NHT on PCRD in a multicenter high-risk PCa population treated with RP, using a propensity-score adjustment. METHODS: This is a retrospective multi-institutional study including patients with high-risk PCa defined as: clinical stage T3-4, PSA >20 ng ml-1 or biopsy Gleason score 8-10. We compared PCRD between RP and NHT+RP using competing risks analysis. Correction for group differences was performed by propensity-score adjustment. RESULTS: After application of the inclusion/exclusion criteria, 1573 patients remained for analysis; 1170 patients received RP and 403 NHT+RP. Median follow-up was 56 months (interquartile range 29-88). Eighty-six patients died of PCa and 106 of other causes. NHT decreased the risk of PCRD (hazard ratio (HR) 0.5; 95% confidence interval (CI) 0.32-0.80; P=0.0014). An interaction effect between NHT and radiotherapy (RT) was observed (HR 0.3; 95% CI 0.21-0.43; P<0.0008). More specifically, of patients who received adjuvant RT, those who underwent NHT+RP had decreased PCRD rates (2.3% at 5 year) compared to RP (7.5% at 5 year). The retrospective design and lack of specific information about NHT are possible limitations. CONCLUSIONS: In this propensity-score adjusted analysis from a large high-risk PCa population, NHT before surgery significantly decreased PCRD. This effect appeared to be mainly driven by the early addition of RT post-surgery. The specific sequence of NHT+RP and adjuvant RT merits further study in the high-risk PCa population.
引用
- Tosco L, Laenen A, Briganti A, et al. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 28485390. doi:10.1038/pcan.2017.29
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。